Niveles de enzimas hepáticas en las pacientes con síndrome de HELLP al ingreso, 12 - 48 horas postparto y egreso del Hospital General Monte Sinaí durante el periodo 2021-2024.

Abstract

Introduction: Maternal death is a public health problem in Ecuador. Hypertensive disorders of pregnancy are one of the main causes of maternal-fetal death. HELLP syndrome is a rare and severe complication where the liver and placenta play a fundamental role in inmunohematological and vascular reactions. It is considered a pathology with a high rate of maternal-fetal morbidity and mortality without timely treatment. Objective: To analyze liver enzyme levels in patients with HELLP syndrome at admission, 12-48 hours postpartum and discharge from Mount Sinai General Hospital during the period 2021-2024. Methodology: This is an observational, analytical, retrospective, longitudinal and quantitative study. It has a population of 139 patients with more than 20 weeks of gestation. Medical records were used to collect the information. Results: bilirubin, AST, AST and LDH levels were measured, where a progressive decrease in liver enzymes was observed. The most frequent complications are seizures (28.06%), renal failure (25.18%) and postpartum hemorrhage (14.39%). The most commonly used antihypertensive regimen is nifedipine + hydralazine (29.50%). The mortality rate in the period 2021-2024 is 17.26%. Conclusion: The progressive decrease in liver enzymes, the absence of liver complications, and the low mortality rate indicate that the clinical-therapeutic management of patients with HELLP syndrome is adequate.